TeneoBio, Inc. is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases.

We use a proprietary sequence-based discovery approach using NGS, bioinformatics, and high-throughput screening to quickly identify a diverse set of leads.

We have produced many high-affinity UniAbs specific for human CD3 and various tumor antigens. These bispecific antibodies are in preclinical development as next-generation T-cell engaging anti-cancer therapeutics.